Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

Company Overview - Arvinas, Inc. is a clinical-stage biotechnology company focused on developing therapies that degrade disease-causing proteins using its proprietary PROTAC Discovery Engine platform [2] - The company aims to improve the lives of patients with debilitating and life-threatening diseases through the discovery, development, and commercialization of these therapies [2] Clinical Programs - Arvinas has a robust preclinical pipeline of PROTAC protein degraders targeting both validated and "undruggable" targets [2] - The company is advancing three investigational clinical-stage programs: - Vepdegestrant (ARV-471) for locally advanced or metastatic ER+/HER2- breast cancer - ARV-766 and bavdegalutamide for metastatic castration-resistant prostate cancer [2] Upcoming Events - Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development will participate in a fireside chat at the 6th Annual Guggenheim Biotechnology Conference on February 7, 2024 [1] - A live audio webcast of the presentation will be available on the company's website [1]